Market capitalization | $360.00k |
Enterprise Value | $110.42m |
P/E (TTM) P/E ratio | 0.00 |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 5.26 |
P/S ratio (TTM) P/S ratio | 0.02 |
P/B ratio (TTM) P/B ratio | 0.00 |
Revenue growth (TTM) Revenue growth | 155.29% |
Revenue (TTM) Revenue | $20.99m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
1 Analyst has issued a forecast Impel NeuroPharma Inc.:
1 Analyst has issued a forecast Impel NeuroPharma Inc.:
Sep '23 |
+/-
%
|
||
Revenue | 21 21 |
155%
155%
|
|
Gross Profit | 9.01 9.01 |
293%
293%
|
|
EBITDA | -68 -68 |
23%
23%
|
EBIT (Operating Income) EBIT | -70 -70 |
21%
21%
|
Net Profit | -74 -74 |
31%
31%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Impel NeuroPharma, Inc. operates as clinical stage biotechnology firm that develops medical devices. It offers intranasal drug treatments for central nervous system (CNS) disorders. The firm product candidates includes TRUDHESA, INP105, and INP107. The company was founded by Rodney J. Y. Ho, John D. Hoekman, and Michael P. Hite in 2008 and is headquartered in Seattle, WA.
Head office | United States |
CEO | Leonard Paolillo |
Founded | 2008 |
Website | impelpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.